Results 21 to 30 of about 5,494 (193)

Aducanumab and the certainty of evidence [PDF]

Age and Ageing, 2021
No abstract available.
McCleery, Jenny, Quinn, Terence J.
openaire   +3 more sources

Aducanumab for Alzheimer’s disease? [PDF]

BMJ, 2021
Patients and families need hope, not false ...
Walsh, Sebastian, Merrick, Richard, Milne, Richard, Brayne, Carol   +3 more
openaire   +2 more sources

Aducanumab for Alzheimer’s disease: The never‐ending story that nurses should know [PDF]

, 2021
In October 2019, the American pharmaceutical company Biogen stated intention to apply to the US Food and Drug Administration (FDA) for the candidate drug aducanumab to be licenced as a therapeutic agent for the treatment of Alzheimer's disease (AD).
Joel Petch, Bressington, Daniel, Petch, J., Daniel Bressington, Bressington, D., Petch, Joel   +5 more
core   +1 more source

“Real world” eligibility for aducanumab [PDF]

Journal of the American Geriatrics Society, 2021
n ...
Canevelli, Marco, Rossi, Paolo Dionigi, Astrone, Paolo, Consorti, Ernesto, Vanacore, Nicola, Cesari, Matteo   +5 more
openaire   +4 more sources

Aducanumab for alzheimer's disease:An update [PDF]

, 2021
The US FDA approved Aducanumab in June 2021 as the first Alzheimer's disease (AD) drug under its accelerated approval pathway. It has given some hope to patients suffering from AD around the world.
Shaikh, Mohd Farooq, Retinasamy, Thaarvena, Mohd. Farooq Shaikh, Thaarvena Retinasamy   +3 more
core   +1 more source

Aducanumab

Reactions Weekly
Introduction and Definition: Aducanumab is “a human monoclonal antibody that selectively targets aggregated Aβ [amyloid-beta protein]”. This has been used as a novel therapy for treating Alzheimer’s disease (AD), as AD is characterized by an accumulation of amyloid plaques in the brain, which are proposed to lead to the cognitive decline attributed to ...
Padda IS, Preuss CV, Parmar M.
europepmc   +5 more sources

Of education and public policy: Aducanumab [PDF]

Journal of the American Geriatrics Society, 2021
See related letter by Padovani et al .
Nancy E, Lundebjerg, Peter A, Hollmann, Mark A, Supiano   +2 more
openaire   +2 more sources

Aducanumab: evidence from clinical trial data and controversies

Drugs in Context, 2021
Alzheimer’s disease (AD) is the most common cause for dementia worldwide. Until recently, all approved treatments for AD were symptomatic and not disease modifying.
Rajesh R Tampi, Brent P Forester, Marc Agronin   +2 more
doaj   +1 more source

ADUCANUMAB NO TRATAMENTO DA DOENÇA DE ALZHEIMER [PDF]

, 2023
Introduction: Alzheimer\u27s disease (AD) is a chronic pathology, characterized by progressive cognitive impairment and neurobehavioral changes. Common treatments for Alzheimer\u27s disease are symptomatic in focus and have modest benefits.
Miguel Neri Beraldo da Silva, Jorge Henrique De Souza Almeida, Nakano Pereira, Pedro, Ana Flávia Fonseca de Oliveira, Tochihide Iamaguti, Felipe, de Oliveira Ferreira, Igor Henrique, Fonseca de Oliveira, Ana Flávia, ´Peruzzi Iamaguti, Júlia, Mendonça Rocha, Carollayne, Alexandre Teixeira do Amaral, de Souza Almeida, Jorge Henrique, Azara Oliveira, Eric, Júlia ´Peruzzi Iamaguti, Felipe Tochihide Iamaguti, Igor Henrique De Oliveira Ferreira, Pedro Nakano Pereira, Eric Azara Oliveira, Carollayne Mendonça Rocha, Teixeira do Amaral, Alexandre, Neri Beraldo da Silva, Miguel   +19 more
core   +1 more source

Aducanumab, a Novel Anti-Amyloid Monoclonal Antibody, for the Treatment of Alzheimer’s Disease: A Comprehensive Review [PDF]

, 2022
Alzheimer’s disease (AD) is the most common form of dementia affecting millions of individuals, including family members who often take on the role as caregiver.
Haddad, Hannah, Kaye, Adam M., Malone, Garett W., Comardelle, Nicholas J., Haddad, Hannah W, Degueure, Arielle E., Kaye, Alan D., Kaye, Alan David, Nicholas J. Comardelle, Adam M. Kaye, Arielle E. Degueure, Garett W. Malone, Alan D. Kaye, Hannah W Haddad   +13 more
core   +1 more source